Molecular mechanisms in thrombotic thrombocytopenic purpura

被引:29
作者
Tsai, HM
机构
[1] Montefiore Med Ctr, Div Hematol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
关键词
thrombotic thrombocytopenic purpura; TTP; metalloprotease; ADAMTS; von Willebrand factor;
D O I
10.1055/s-2004-835675
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia and microangiopathic hemolysis. Unlike the typical hemolytic uremic syndrome (HUS), which follows infection with shiga toxin-producing microorganisms, most cases of TTP do not have an obvious etiology. Recent studies revealed that a plasma zinc metalloprotease ADAMTS (a disintegrin and metalloprotease with thrombospondin type 1 motif) 13 cleaves von Willebrand factor in a shear-dependent manner. Deficiency of ADAMTS13, due to autoimmune inhibitors of the protease or genetic mutation in the ADAMTS13 gene, results in a propensity to the development of von Willebrand factor-platelet aggregation and intravascular thrombosis characteristic of TTP. The identification of the molecular defect in TTP raises the prospect that this hitherto mysterious disorder will be managed with a more rationally designed strategy in the near future.
引用
收藏
页码:549 / 557
页数:9
相关论文
共 71 条
[41]  
ROMANI DW, 2003, J HAEMATOL, V123, P522
[42]   ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity [J].
Savasan, S ;
Lee, SK ;
Ginsburg, D ;
Tsai, HM .
BLOOD, 2003, 101 (11) :4449-4451
[43]   Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP [J].
Schneppenheim, R ;
Budde, U ;
Oyen, F ;
Angerhaus, D ;
Aumann, V ;
Drewke, E ;
Hassenpflug, W ;
Häberle, J ;
Kentouche, K ;
Kohne, E ;
Kurnik, K ;
Mueller-Wiefel, D ;
Obser, T ;
Santer, R ;
Sykora, KW .
BLOOD, 2003, 101 (05) :1845-1850
[44]   STUDIES ON THROMBOPOESIS .1. A FACTOR IN NORMAL HUMAN PLASMA REQUIRED FOR PLATELET PRODUCTION - CHRONIC THROMBOCYTOPENIA DUE TO ITS DEFICIENCY [J].
SCHULMAN, I ;
PIERCE, M ;
LUKENS, A ;
CURRIMBHOY, Z .
BLOOD, 1960, 16 (01) :943-957
[45]   LATE RELAPSES IN PATIENTS SUCCESSFULLY TREATED FOR THROMBOTIC THROMBOCYTOPENIC PURPURA [J].
SHUMAK, KH ;
ROCK, GA ;
NAIR, RC ;
ADAMS, G ;
BENNY, B ;
BUSKARD, NA ;
CAPLAN, S ;
CARD, R ;
CLARK, WF ;
FORD, P ;
FREEDMAN, J ;
GORDON, P ;
GORELICK, M ;
KELTON, J ;
KLASSEN, J ;
LEBLOND, P ;
LEPINEMARTIN, M ;
MCBRIDE, J ;
MONTE, M ;
RAYNER, H ;
SHORE, T ;
STERNBACH, M ;
SUTTON, DMC ;
JONES, JV .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (08) :569-572
[46]  
SIDDIQUI FA, 1992, BIOCHEM INT, V27, P485
[47]   Shear-dependent changes in the three-dimensional structure of human von Willebrand factor [J].
Siedlecki, CA ;
Lestini, BJ ;
KottkeMarchant, K ;
Eppell, SJ ;
Wilson, DL ;
Marchant, RE .
BLOOD, 1996, 88 (08) :2939-2950
[48]   A novel human metalloprotease synthesized in the liver and secreted into the blood: Possibly, the von Willebrand factor-cleaving protease? [J].
Soejima, K ;
Mimura, N ;
Hirashima, M ;
Maeda, H ;
Hamamoto, T ;
Nakagaki, T ;
Nozaki, C .
JOURNAL OF BIOCHEMISTRY, 2001, 130 (04) :475-480
[49]   ADAMTS: a novel family of extracellular matrix proteases [J].
Tang, BL .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2001, 33 (01) :33-44
[50]   Complement factor H and the haemolytic uraemic syndrome [J].
Taylor, CM .
LANCET, 2001, 358 (9289) :1200-1202